Bladder Cancer News and Research RSS Feed - Bladder Cancer News and Research

In North America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year. In addition, the cancers of many previously-diagnosed patients remain unresolved, sometimes leading to cystectomy (bladder removal) or death. Approximately 70% bladder cancer patients have the non-muscle-invasive form of bladder cancer at diagnosis.
Simple urine test could guide clinicians to better treat bladder cancer patients

Simple urine test could guide clinicians to better treat bladder cancer patients

Researchers at the University of Birmingham believe that a simple urine test could help to guide clinicians in the treatment of bladder cancer patients. [More]
Findings may help doctors recommend appropriate treatments, improve patient outcomes

Findings may help doctors recommend appropriate treatments, improve patient outcomes

Like a car's front and back bumpers, your cell's chromosomes are capped by "telomeres" that protect this genetic material against deterioration. Still, after enough replications, a chromosome's telomeres break down and once they reach a certain point of degradation, the cell dies. This is one reason that cells are mortal: telomeres only last so long. That is, unless the enzyme telomerase builds new material onto the worn telomeres to reinforce these chromosomal "bumpers". Telomere repair can be a good thing, but in some cases it's not: overactive telomerase can lengthen telomeres until a cell becomes immortal…leading to cancer. [More]
Tissue and cell diagnostics market reaches $7.7 billion in 2014

Tissue and cell diagnostics market reaches $7.7 billion in 2014

With fast and effective testing techniques, the tissue and cell diagnostics market was estimated to have reached $7.7 billion in 2014 for in vitro diagnostic (IVD) and other reagents used by clinical laboratories, according to Kalorama Information. [More]
CellDetect urine test for detecting bladder cancer meets primary endpoint in multi-center clinical study

CellDetect urine test for detecting bladder cancer meets primary endpoint in multi-center clinical study

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that a blinded, multi-center clinical study of the CellDetect non-invasive test for detecting bladder cancer in urine, successfully achieved the study's primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of the disease. [More]
Breast and lung cancer patients with low levels of TTP protein have poorer prognosis

Breast and lung cancer patients with low levels of TTP protein have poorer prognosis

Moffitt Cancer Center researchers have found that breast and lung cancer patients who have low levels of a protein called tristetraprolin (TTP) have more aggressive tumors and a poorer prognosis than those with high levels of the protein. [More]
Signostics gets FDA 510k clearance for handheld bladder scanner

Signostics gets FDA 510k clearance for handheld bladder scanner

Medical device company, Signostics, announced today it has clearance from the U.S. Food and Drug Administration to launch the SignosRT Bladder, the company’s new hand-held bladder scanner. [More]
Laparoscopic radical cystectomy can lead to reliable, long-term cancer control

Laparoscopic radical cystectomy can lead to reliable, long-term cancer control

Long-term survival rates following laparoscopic surgery for bladder cancer are comparable to those of open surgery, according to a study published in BJU International. The findings, which come from the largest study to date with long-term follow-up after this type of minimally invasive surgery, indicate that prospective randomized trials comparing these two bladder cancer surgeries are warranted. [More]
Olympus receives FDA clearance for Narrow Band Imaging

Olympus receives FDA clearance for Narrow Band Imaging

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today FDA 510(k) clearance of Narrow Band Imaging (NBI) as enabling effective targeting of biopsies not seen under white light and improved visualization of tumor boundaries in Non-Muscle-Invasive Bladder Cancer (NMIBC) patients. [More]
Nivolumab drug highly effective for Hodgkin's lymphoma

Nivolumab drug highly effective for Hodgkin's lymphoma

A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments. [More]
Immune-suppressing protein may predict how patients respond to treatment

Immune-suppressing protein may predict how patients respond to treatment

The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found. [More]
Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years. [More]
Study identifies genetic alterations that contribute to growth and recurrence of Ewing sarcoma

Study identifies genetic alterations that contribute to growth and recurrence of Ewing sarcoma

An international collaboration has identified frequent mutations in two genes that often occur together in Ewing sarcoma (EWS) and that define a subtype of the cancer associated with reduced survival. [More]
Cigarette smoking increases risk of developing second smoking-associated cancer

Cigarette smoking increases risk of developing second smoking-associated cancer

Results of a federally-funded pooled analysis of five prospective cohort studies indicate that cigarette smoking prior to the first diagnosis of lung (stage I), bladder, kidney or head and neck cancer increases risk of developing a second smoking-associated cancer. This is the largest study to date exploring risk of second cancers among current smokers. [More]
Arsenic levels exceed in some rice-based foods, can affect celiac disease sufferers

Arsenic levels exceed in some rice-based foods, can affect celiac disease sufferers

Rice is one of the few cereal grains consumed by people with celiac disease, as it does not contain gluten. However, it can have high concentrations of a toxic substance – arsenic – as revealed by the analyses of flour, cakes, bread, pasta and other foods made with rice, conducted by researchers from the Miguel Hernández University of Elche, Spain. [More]
Five bladder cancer experts to receive $250,000 research grants from Johns Hopkins

Five bladder cancer experts to receive $250,000 research grants from Johns Hopkins

Five bladder cancer experts will be awarded research grants totaling $250,000 from the Johns Hopkins Greenberg Bladder Cancer Institute on Oct. 15. The grant awards will be the centerpiece of a day-long board meeting. The event will culminate with the unveiling of a ceremonial plaque marking the establishment of the new institute that was made possible with a landmark gift from Baltimore-area commercial real estate developer Erwin Greenberg and his wife, Stephanie Cooper Greenberg. [More]
Bioniche Life Sciences announces year-end results for fiscal 2014, provides corporate update

Bioniche Life Sciences announces year-end results for fiscal 2014, provides corporate update

Bioniche Life Sciences Inc. today announced financial results for its fiscal year ended June 30, 2014. [More]

MT Services reports Actos drug cases, updates settlement news

MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today a primary focus on assisting plaintiffs of the after effects of the pharmaceutical drug Actos. [More]
Collaborative study takes important step toward finding targeted treatments for bladder cancer

Collaborative study takes important step toward finding targeted treatments for bladder cancer

The story of cancer care seems so simple: find the mutated gene that causes cancer and turn it off or fix it. But rarely does a single gene cause cancer. More often, many genes are altered together to drive the disease. So the challenge becomes sorting out which altered genes are the most to blame in which cancers. [More]

Pacific Edge signs agreement with SCPMG to evaluate Cxbladder User Program

Pacific Edge Ltd, a cancer diagnostics company, has signed an agreement with Southern California Permanente Medical Group (SCPMG) to research its User Program to evaluate its bladder cancer technology Cxbladder within the clinical settings of Kaiser Permanente's health care network. [More]

Invisible blood in urine: An early warning sign of bladder cancer

New research which finds that invisible blood in urine may be an early warning sign of bladder cancer is likely to shape guidelines for clinicians. [More]